

Supporting Table

Table S1. Primers Used in qRT-PCR.

Gene	Forward primer	Reverse primer
β -actin (human)	GGGAAATCGTGCGTGACATT	GGAACCGCTCATTGCCAAT
BAX (human)	TGGCAGCTGACATGTTTTCTG	TCCCGGAGGAAGTCCAATG
CASP3 (human)	AGAAATTGTGGAATTGATGCGTG	AGAAATTGTGGAATTGATGCGTG
SOD (human)	ATGGTGTGGCCGATGTGTCT	AAACGACTTCCAGCGTTTCCT
HMOX1 (human)	ACACCCAGGCAGAGAATGCT	CGAAGACTGGGCTCTCCTTGT
CAT (human)	GCTGAGGTTGAACAGATAGCCTTC	CACTCGAGCACGGTAGGGA
IL6 (human)	TGGCTGAAAAAGATGGATGCT	TCTGCACAGCTCTGGCTTGT

Table S2. P/TiO₂ NPs ICP-AES Characterization Results.

Chemical element	Element content
P	6.2940%
Ti	47.3884%

Table S3. Doping Amount of P in P/TiO₂ NPs.

Doping element	Actual doping amount	Theoretical doping amount
P	7.37%	16.67%

Supporting Figures




Figure S1. Chemical structure of fluorescence probes of $^1\text{O}_2$ (a), $\bullet\text{O}_2^-$ (b), H_2O_2 (c) and $\bullet\text{OH}$ (d).




Figure S2. (a) Instrument-derived data for DLS size distribution of P/TiO₂ NPs. (b) XPS survey spectra of TiO₂, phosphorus and P/TiO₂ composites. (c) Raman spectra of TiO₂, phosphorus and P/TiO₂ composites.




Figure S3. (a) The impact of different phosphorus doping ratios on the cytotoxicity of TiO₂ to 786-O cells in the presence or absence of NIR laser exposure. (P/TiO₂-1:x, x=2.5, 5, 7.5, 10)




Figure S4. Blood biochemistry examinations (Scr (a), BUN (b), UA (c), ALT (d), AST (e), TP (f), TBIL (g), DBIL (h), IBIL (i)) of mice after intravenous injection with P/TiO₂ NPs for 1, 7, and 14 days. Scr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; ALT, glutamic pyruvic transaminase; AST, glutamic oxalacetic transaminase; TP, total protein; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin.




Figure S5. H&E staining studies of heart, liver, spleen, lung, and kidney tissues of male (a) and female (b) mice at 1, 7, and 14 d after intravenous injection of P/TiO₂ NPs.




Figure S6. (a) Detection of ROS generation in 786-O cells by P/TiO₂ NPs after treatment with 808 nm NIR at different power densities/fluence for 10 min. (b) The fluorescence density was quantified by ImageJ software to establish the light dose response curve with increasing fluence.




Figure S7. Changes of mRNA expression of Bax (a), Caspase-3 (b), SOD (c), HO-1 (d), CAT (e) and IL-6 (f) in HK-2 cells after P/TiO₂ NPs and PDT/PTT treatments. *: $p < 0.05$ and ***: $p < 0.001$ vs control.




Figure S8. (a) and (c) Temperature images of different tumor-bearing mice. The maximum temperature was indicated respectively. (b) The pattern diagram of the animal research design.




Figure S9. (a) Weight changes in tumor-bearing mice were treated with saline, DOX, P/TiO₂ NPs, and P/TiO₂ NPs+NIR for 7 days, respectively.




Figure S10. (a) Volumes and (b) weights of 786-O tumors after treatment with saline, DOX, P/TiO₂ NPs and P/TiO₂ NPs+NIR for 7 days, respectively.




Figure S11. (a) Immunohistochemical evaluation of Caspase-3 in 786-O tumors post-treatment, where blue denotes nuclei and brown signifies Caspase-3 expression.